Iovance Biotherapeutics Q2 2024 Adj EPS $(0.34) Beats $(0.35) Estimate, Sales $31.11M Beat $24.59M Estimate
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics (NASDAQ:IOVA) reported Q2 2024 adjusted EPS of $(0.34), beating the estimate of $(0.35). Sales were $31.11M, surpassing the $24.59M estimate and showing a significant increase from $238K last year.
August 08, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics reported better-than-expected Q2 2024 results with an EPS of $(0.34) beating the $(0.35) estimate and sales of $31.11M surpassing the $24.59M estimate. This represents a significant year-over-year sales increase.
The better-than-expected EPS and significant sales growth indicate strong performance, likely leading to positive short-term stock price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100